Source: Eur Respir J 2011; 37: 888-894



Rating:

Share or cite this content

Citations should be made in the following way:
Máthé C., Bohács A., Duffek L., Lukácsovits J., Komlosi Z.I., Szondy K., Horváth I., Müller V., Losonczy G.. Cisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patients. Eur Respir J 2011; 37: 888-894

Member's Comments

No comment yet.

Related content which might interest you: Systemic manifestations and comorbidities of COPD Source: Eur Respir J 2009; 33: 1165-1185 Year: 2009 Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD Source: Eur Respir J 2008; 32: 962-969 Year: 2008 Relationship between lung function impairment and incidence or recurrence of cardiovascular disease in a middle-aged cohort Source: Annual Congress 2007 - Longitudinal and cross sectional risk factors for COPD Year: 2007 Incidence of lung cancer in collagen vascular diseases (CVD) Source: Eur Respir J 2005; 26: Suppl. 49, 321s Year: 2005 The evaluation of systemic inflammation in COPD patients comorbided with cardiovascular diseases or diabetes mellitus Source: Annual Congress 2011 - Respiratory epidemiology: comorbidity Year: 2011 Increased survival in lung cancer patients with diabetes mellitus: A large cohort study Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 Does diabetes mellitus influence the prognosis of patients with lung cancer? Source: Annual Congress 2013 –Other thoracic tumours, particular circumstances and rare cases Year: 2013 Impact of diabetes mellitus (dm) or hypertension and ischaemic heart disease (hd) on cisplatin nephrtotoxicity Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009 Is lung a target organ in diabetes mellitus? Source: Eur Respir J 2002; 20: Suppl. 38, 491s Year: 2002 Subsequent COPD and lung cancer in patients with autoimmune disease Source: Eur Respir J 2011; 37: 463 Year: 2011 Impact of diabetes mellitus on survival and hospitalization after lung transplantation Source: International Congress 2016 – Post-transplant complications: from animal models to the bedside Year: 2016 Severe pulmonary hypertension leading to heart–lung transplantation and revealing breast cancer}, Source: Eur Respir J 2012; 40: 1057-1059 Year: 2012 COPD prevalence is increased in lung cancer, independent of age, sex and smoking history Source: Eur Respir J 2009; 33: 380-386 Year: 2009 Is sildenafil an effective bridging therapy to lung transplantation for patients with pulmonary hypertension in the setting of lung disease? Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015 Comorbidities in lung cancer progression Source: International Congress 2017 – ME12 Comorbidities in lung cancer progression Year: 2017 Drug-induced infiltrative lung disease Source: Eur Respir J 2001; 18: 93S-100S Year: 2001 Discharge support and readmission of older patients with lung cancer Source: Annual Congress 2007 - Nurses' involvement in the follow-up of patients with COPD and lung cancer Year: 2007 Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients Source: Eur Respir J, 50 (2) 1700050; 10.1183/13993003.00050-2017 Year: 2017 Osteoporosis in end-stage lung disease Source: Eur Respir Mon; 2009: 45: 62–78 Year: 2009 Effect of cardiovascular comorbidities on the survival patients with stage I and II non-small-cell lung cancer Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011